№ files_lp_4_process_2_61627
File format: docx Character count: 1120 File size: 23 KB
Year: 2016
Location: La Roche Chalais, France
Type of document: Press release
Organization: KSB Aktiengesellschaft
Author: Dr Buthmann, Member of the Board of Management
Industry: Industrial valves manufacturing
Target audience: Industry professionals, media
Purpose: Announcement of facility inauguration and production capabilities
Facility size: 4,400 square metres
Production focus: Triple-offset high-performance butterfly valves up to DN 1200
Applications: Liquefaction, gasification, natural gas transport, offshore and onshore facilities
Construction duration: Nearly two years
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Continuity at the helm of KSB Group management until 2027/2029
Year: 2026
Company: KSB Group
Location: Frankenthal, Germany
Document type: Press release
Topic: Management contract extensions and corporate leadership
CEO: Dr Stephan Timmermann
CTO: Stephan Bross
CSO: Ralf Kannefass
CFO: Dr Matthias Schmitz
Management contract end dates: Dr Stephan Timmermann – 31 December 2027, Ralf Kannefass and Dr Matthias Schmitz – 2029
Workforce: approximately 16,400
Sales revenue: ~€3 billion (2024)
Global presence: five continents
ALECTINIB, Capsule 150 mg, Alecensa® ROCHE PRODUCTS PTY LTD
Year: 2024
Region / city: Australia
Topic: Pharmacological treatment
Document type: Pharmaceutical submission
Agency / institution: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: Unknown
Target audience: Medical practitioners, healthcare professionals
Period of validity: Not specified
Approval date: 23 December 2024
Date of amendments: Not specified
ATEZOLIZUMAB, Solution concentrate for I.V. infusion 840 mg in 14 mL, Solution concentrate for I.V. infusion 1,200 mg in 20 mL, Tecentriq®, Roche Products Pty Ltd
Year: 2023
Region / City: Australia
Theme: Oncology, Lung Cancer
Document Type: Medical Submission
Organization / Institution: Roche Products Pty Ltd
Author: Not specified
Target Audience: Medical professionals, healthcare providers
Period of Validity: Ongoing
Approval Date: Not specified
Date of Changes: Not specified
Risk Assessment for Blood Gas Analysers - Roche Cobas b221 in COVID-19 Suspected or Confirmed Patients
Year: 2020
Region / city: Not specified
Subject: Risk assessment of blood gas analysers for COVID-19 patients
Document type: Risk assessment report
Organization: Not specified
Author: Nicola Hodges, Katy Lomas, Kyle Day
Target audience: Medical staff, laboratory personnel
Period of validity: 12/03/2020 - 12/09/2020
Approval date: 12/03/2020
Date of changes: Not specified
ATEZOLIZUMAB, solution concentrate for I.V. infusion 1200 mg in 20 mL, solution concentrate for I.V. infusion 840 mg in 14 mL, Tecentriq® plus BEVACIZUMAB, solution for I.V. infusion 100 mg in 4 mL, solution for I.V. infusion 400 mg in 16 mL, Avastin®, Roche Products Pty Ltd
Year: 2020
Region / city: Australia
Topic: Cancer Treatment, Pharmacology
Document type: Submission for Pharmaceutical Listing
Organization / institution: Roche Products Pty Ltd
Author: Unknown
Target audience: Pharmaceutical regulators, healthcare professionals
Validity period: Ongoing review process
Approval date: 2020-01-10
Amendment date: Not specified
Linearity and reference limits of Roche Elecsys TnT hs Gen 6 on Cobas e801
Year: 2026
Region / city: International
Topic: Cardiac biomarkers
Document type: Supplementary figure
Organization / institution: Roche Diagnostics
Author: Roche Research Team
Target audience: Clinical laboratory professionals
Sample size: 815 healthy blood donors
Sex distribution: 429 men, 386 women
Analyte: Cardiac troponin T (cTnT)
Method: Roche Elecsys TnT hs Gen 6 immunoassay on Cobas e801
Statistical data: 99th percentile upper reference limits with 95% confidence intervals
Party Booking Form for Roche Park Recreation Centre
Year: Not specified
Location: Roche Park Recreation Centre, Collie
Document Type: Booking form
Organization: Roche Park Recreation Centre
Target Audience: Parents/guardians booking parties for children
Booking Period: Not specified
Payment Details: Hourly rates for playroom and court hire, extra costs for damages
Conditions: Cancellation policy, cleaning requirements, damage responsibility, non-smoking policy, emergency procedures
Activities Included: Playroom hire, court hire, roller skating, Nerf themed, dance themed
Equipment Provided: Bouncy castle, playroom equipment, roller skates, helmets, lights, music setup
Facility Hire Application Form – Roche Park Recreation Centre, Collie WA
Year: 2026
Location: Collie, Western Australia
Document Type: Application Form
Organization: Shire of Collie
Facility: Roche Park Recreation Centre
Purpose: Hire of sports courts, function rooms, meeting rooms, kitchen, kiosk, and associated equipment
Target Audience: Individuals or organizations seeking to hire facilities
Requirements: Completed application form, copy of liquor license if alcohol will be consumed or sold, proof of insurance
Booking Conditions: Cancellation policy, cleaning requirements, conduct rules, emergency procedures
Cost Information: Room hire rates, equipment hire fees, additional staffing charges
Date Issued: 2026
Contact: [email protected]
Note: , Phone 08 9734 4388
Topics: Chalais KSB ROCHE